Related references
Note: Only part of the references are listed.RECIST 1.1-Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin et al.
LANCET ONCOLOGY (2015)
Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Charles Ferte et al.
CLINICAL CANCER RESEARCH (2014)
Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice
Andrew G. Robinson et al.
EUROPEAN JOURNAL OF CANCER (2014)
The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases
Gaia Schiavon et al.
EUROPEAN JOURNAL OF CANCER (2014)
Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
N. Penel et al.
ANNALS OF ONCOLOGY (2013)
Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Ronald L. Korn et al.
CLINICAL CANCER RESEARCH (2013)
Progression-Free Survival: Meaningful or Simply Measurable?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Beth Sherrill et al.
ONCOTARGETS AND THERAPY (2012)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Cancer clinical trial outcomes: Any progress in tumour-size assessment?
Jaap Verweij et al.
EUROPEAN JOURNAL OF CANCER (2009)
Individual patient data analysis to assess modifications to the RECIST criteria
Jan Bogaerts et al.
EUROPEAN JOURNAL OF CANCER (2009)
Validation of novel imaging methodologies for use as cancer clinical trial end-points
D. J. Sargent et al.
EUROPEAN JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Issues in Using Progression-Free Survival When Evaluating Oncology Products
Thomas R. Fleming et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Specific growth rate versus doubling time for quantitative characterization of tumor growth rate
Esmaeil Mehrara et al.
CANCER RESEARCH (2007)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint
R Mick et al.
CONTROLLED CLINICAL TRIALS (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
